scholarly journals Complete Remission of Anaplastic Thyroid Carcinoma after Concomitant Treatment with Docetaxel and Radiotherapy

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Ichiro Abe ◽  
Satoko Karasaki ◽  
Yayoi Matsuda ◽  
Shohei Sakamoto ◽  
Torahiko Nakashima ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Survival Rate ◽  
Mortality Rate ◽  
Complete Remission ◽  
Thyroid Carcinoma ◽  
Therapeutic Potential ◽  
Anaplastic Thyroid Carcinoma ◽  
High Dose ◽  
Concomitant Treatment ◽  
Very High

Anaplastic thyroid carcinoma (ATC) although rare is the most lethal form of thyroid cancer. The mortality rate for ATC is very high, with a median survival time of only 5 months; the survival rate at 1 year after diagnosis is <20%. Management of ATC is extremely difficult and rife with uncertainties. Herein, we describe a 75-year-old woman who presented with ATC and was successfully treated using concomitant treatment with docetaxel and high-dose radiotherapy. This case appears to be the first to have been reported in the literature involving complete remission of ATC confirmed by autopsy, suggesting the therapeutic potential of this combination.

Long-Term Remission in a Case of Anaplastic Thyroid Carcinoma following Local Irradiation and High-Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation

2007 ◽  
Vol 1 ◽  
pp. CMO.S435
Author(s):  
Koji Kato ◽  
Yuju Ohno ◽  
Shoshu Mitsuyama ◽  
Satoshi Toyoshima ◽  
Junichi Ito ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Thyroid Carcinoma ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
High Dose Chemotherapy ◽  
Anaplastic Thyroid Carcinoma ◽  
High Dose ◽  
Blood Stem Cell Transplantation

Anaplastic thyroid carcinoma (ATC) is a tumor with bad prognosis and long-term survival is very low. However, appropriate combinations of chemotherapy, surgery, and radition have been reported to potentially improve the treatment results for ATC. We describe a case of refractory ATC successfully treated with high-dose chemotherapy (HDC) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT). There has not been any evidence of recurrence for 10 years after auto-PBSCT. To the best of our knowledge, this is the first case of ATC that has been followed up for a long-term period after HDC with auto-PBSCT. This case suggests that intensive therapeutic approach such as HDC with auto-PBSCT may be useful.

scholarly journals Thyroid Carcinoma with Pituitary Metastases: 2 Case Reports and Literature Review

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Weiying Lim ◽  
Dawn Shaoting Lim ◽  
Chiaw Ling Chng ◽  
Adoree Yiying Lim
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Follicular Thyroid Carcinoma ◽  
Case Reports ◽  
Anaplastic Thyroid Cancer ◽  
Anaplastic Thyroid Carcinoma ◽  
Pituitary Metastases ◽  
History Of ◽  
Loss Of Appetite

We present 2 patients with pituitary metastases from thyroid carcinoma—the first from anaplastic thyroid carcinoma and the second from follicular thyroid carcinoma. The first patient, a 50-year-old lady, presented with 2-week history of hoarseness of voice, dysphagia, dyspnoea, and neck swelling. Imaging revealed metastatic thyroid cancer to lymph nodes and bone. Histology from surgery confirmed anaplastic thyroid cancer. She was found to have pituitary metastases postoperatively when she presented with nonvertiginous dizziness. She subsequently underwent radiotherapy and radioiodine treatment but passed away from complications. The second patient, a 65-year-old lady, presented with loss of appetite and weight with increased goitre size and dyspnoea. Surgery was performed in view of compressive symptoms and histology confirmed follicular thyroid carcinoma. Imaging revealed metastases to bone, lung, and pituitary. She also had panhypopituitarism with hyperprolactinemia and diabetes insipidus. She received radioiodine therapy but eventually passed away from complications.

scholarly journals Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1532 ◽  
Author(s):  
Malfitano ◽  
Somma ◽  
Prevete ◽  
Portella
Keyword(s):  
Thyroid Carcinoma ◽  
Therapeutic Potential ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Differentiated Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Oncolytic Viruses ◽  
Cancer Models ◽  
Poorly Differentiated ◽  
Immunosuppressive Microenvironment

Virotherapy is a novel cancer treatment based on oncolytic viruses (OVs), which selectively infect and lyse cancer cells, without harming normal cells or tissues. Several viruses, either naturally occurring or developed through genetic engineering, are currently under investigation in clinical studies. Emerging reports suggesting the immune-stimulatory property of OVs against tumor cells further support the clinical use of OVs for the treatment of lesions lacking effective therapies. Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC), have a poor prognosis and limited treatment options. Therefore, several groups investigated the therapeutic potential of OVs in PDTC/ATC models producing experimental data sustaining the potential clinical efficacy of OVs in these cancer models. Moreover, the presence of an immunosuppressive microenvironment further supports the potential use of OVs in ATC. In this review, we present the results of the studies evaluating the efficacy of OVs alone or in combination with other treatment options. In particular, their potential therapeutic combination with multiple kinases inhibitors (MKIs) or immune checkpoint inhibitors are discussed.

Prognostic Impact of Different High Risk Features in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2303-2303
Author(s):  
Theis Terwey ◽  
Philipp Hemmati ◽  
Gero Massenkeil ◽  
Bernd Dörken ◽  
Renate Arnold
Keyword(s):  
Overall Survival ◽  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
High Risk ◽  
Complete Remission ◽  
Lymphoblastic Leukemia ◽  
High Dose ◽  
Prognostic Impact ◽  
Very High ◽  
First Complete Remission

Abstract Abstract 2303 Poster Board II-280 Introduction: In acute lymphoblastic leukemia (ALL) specific clinical and biological features confer high relapse risk and inferior overall survival (OS) after treatment with conventional chemotherapy alone. The differential prognostic impact of these high risk features after treatment with allogeneic hematopoietic stem cell transplantation (HCT) has not been well studied. Patients and Methods: 79 adult ALL patients in first complete remission (CR) received allogeneic HCT at our center between 1995 and 2008. All patients were high or very high risk according to German Multicenter Study Group for Adult ALL (GMALL) criteria. Median age was 36 years (range: 17-68). Patients received high-dose conditioning consisting of 12 Gy total body irradiation ± etoposide ± cyclophosphamide (n=69, 87%) or reduced intensity conditioning (RIC) consisting of fludarabine/busulfan/ATG (n=10, 13%) and HSCT from related (n=34, 43%) or unrelated (n=45, 57%) donors. Bone marrow (n=17, 22%) or peripheral blood stem cells (n=62, 78%) were given. Graft-versus-host-disease prophylaxis was CSA/MTX for high-dose conditioning or CSA/MMF for RIC. Results: Patients were classified as high risk or very high risk due to Philadelphia chromosome-positive disease (Ph+) (n=30, 38%), leukocytosis>30/nl at diagnosis in B-ALL (n=25, 23%), late response to induction therapy in B-ALL (>week 4) (n=13, 16%), early or mature T-ALL (n=13, 16%), pro-B-ALL/t(4;11) (n=8, 10%), persistence of minimal residual disease (MRD) (>week 16) (n=8, 10%) or complex aberrant karyotype (n=6, 8%). 57 patients (72%) presented with one high risk feature, whereas 20 patients (25%) and 2 patients (3%) presented with two or three features, respectively. Currently, after a median follow-up of 56 months (7-169) 49 patients (62%) remain alive. Projected OS of the whole cohort at 1, 2 and 5 years was 78%, 70% and 55% and leukemia-free survival was 77%, 66% and 55%. Cumulative incidence of non-relapse mortality (NRM) and relapse mortality (RM) at 5 years was 23% and 18%, respectively. In multivariate Cox regression analysis, a non-significant trend for inferior OS was seen for patients with early or mature T-ALL (hazard ratio (HR): 2.03 (95%CI: 0.92-4.52), p=0.082), whereas no differential effect on OS, NRM or RM was seen for any other high risk feature (Table 1). In additional analyses, inferior OS (HR 1.81 (95%CI: 1.02-3.29), p=0.043) and increased RM (HR 2.17 (95%CI 1.16-4.05), p=0.015) was observed for patients with more than one high risk feature. Conclusions: In summary, this single center study on allogeneic HCT in high risk ALL found a negative prognostic trend for early or mature T cell immunophenotype. No differential prognostic impact on OS, NRM and RM was seen for other high risk features as defined by GMALL criteria, however this conclusion is limited by the low patient number in some of the subgroups. Overall survival for the whole cohort was 55% at 5 years, with inferior OS and higher RM being observed in patients with more than one high risk feature. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Short Course High Dose Radiotherapy in the Treatment of Anaplastic Thyroid Carcinoma

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Mark J. Stavas ◽  
Eric T. Shinohara ◽  
Albert Attia ◽  
Matthew S. Ning ◽  
Jeffrey M. Friedman ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Local Control ◽  
Radiation Treatment ◽  
Anaplastic Thyroid Carcinoma ◽  
High Dose ◽  
Treatment Schedule ◽  
Local Progression ◽  
Short Course ◽  
Metastatic Setting ◽  
Hypofractionated Radiation

Purpose. Anaplastic thyroid carcinoma (ATC) is a rare but aggressive tumor with limited survival. To date, the ideal radiation treatment schedule, one that balances limited survival with treatment efficacy, remains undefined. In this retrospective series we investigate the effectiveness and tolerability of hypofractionated radiation therapy in the treatment of ATC.Methods. 17 patients with biopsy proven ATC treated between 2004 and 2012 were reviewed for outcomes and toxicity. All patients received short course radiation.Results. The most commonly prescribed dose was 54 Gy in 18 fractions. Median survival was 9.3 months. 47% of patients were metastatic at diagnosis and the majority of patients (88%) went on to develop metastasis. Death from local progression was seen in 3 patients (18%), 41% experienced grade 3 toxicity, and there were no grade 4 toxicities.Conclusions. Here we demonstrated the safety and feasibility of hypofractionated radiotherapy in the treatment of ATC. This approach offers shorter treatment courses (3-4 weeks) compared to traditional fractionation schedules (6-7 weeks), comparable toxicity, local control, and the ability to transition to palliative care sooner. Local control was dependent on the degree of surgical debulking, even in the metastatic setting.

scholarly journals Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1971-1971
Author(s):  
Kalyan Nadiminti ◽  
Kamal Kant Singh Abbi ◽  
Annick Tricot ◽  
Allyson Schultz ◽  
Lindsay Dozeman ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Mortality Rate ◽  
Conflicts Of Interest ◽  
Residual Disease ◽  
High Dose ◽  
Cell Transplant ◽  
Color Flow ◽  
Preparative Regimen ◽  
Very High

Abstract Background: Melphalan 200mg/m2 is the standard preparative regimen in MM and addition of other cytotoxic drugs has not been found to result in superior activity. The novel agents have improved outcome in MM significantly, but data on their role in preparative regimens are scarce. The purpose of this study was to understand the toxicity and efficacy of triple therapy with VDT in combination with high-dose melphalan. Methods: An IRB approved retrospective analysis was performed on all patients who received an ASCT with the VDT-Mel during 2012-2014. Mel: 100 mg/m2 was given on days -4 and -1; V: 1 mg/m2 on days -4, -1, +2 and +5; T: 100 mg daily from -5 to +5; and D: 20 mg/day from -4 to -1 and +2 to +5. End points were treatment-related toxicity during the first 100 days and quality of response at 6 months post-transplant; 98 patients had follow-up ≥ 6 months. Patients in sCR were also minimal residual disease negative (MRD-) by 10-color flow cytometry with a sensitivity of 10-4. Results: 100 patients received 153 transplants; 47 patients underwent single and 53 had tandem transplants (TT); 64 patients received early (≤ 12 months of induction therapy) and 36 salvage transplantation. Median age was 61 y; median followup was 16.2 months. Only 1patient had achieved a sCR and 11 a CR prior to transplantation. Best responses at 6 months were 53% sCR (and MRD-), 24% CR, and 9% VGPR. The sCR rate after single transplant was 47% (overall) and 54% (early transplant) vs 59% and 60% after TT. Grade 3-5 non-hematologic toxicities were almost entirely related to infections (38% and 53% in single and TT, respectively); the 100-day mortality rate was 2.6% (4/153), 1.8% for early transplants and 4.5% for salvage transplants. Median time to ANC recovery > 500/µL was 12 days in both early and salvage transplantation. Conclusion: VDT-Mel is well-tolerated and resulted in minimal additional toxicity and a similar mortality rate when compared to historic data of MEL alone. Importantly, the sCR rate with MRD- by flow cytometry at 6 months in our study was very high compared to published reports. The ultimate sCR rate will be higher as at this time an additional 13 patients attained a sCR during further follow up past 6 months for a total of 66% sCR. Since both sCR and MRD- are proven early surrogate markers for progression-free and overall survival, it appears highly likely that this regimen will be superior to Mel alone and should become the new standard for ASCT in myeloma. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.

Sodium Alginate Microspheres Tissue Metabolism and Correlation Between Interventional Treatment of Liver Cancer Using Alginate Microspheres and Prognosis of Liver Cancer

2019 ◽  
Vol 9 (7) ◽  
pp. 988-991
Author(s):  
Jinghua Huang ◽  
Yongan Fu ◽  
Zongda Cai
Keyword(s):  
Survival Rate ◽  
Mortality Rate ◽  
Liver Cancer ◽  
Complete Remission ◽  
Sodium Alginate ◽  
Remission Rate ◽  
Correlation Equation ◽  
Complete Remission Rate ◽  
Interventional Treatment ◽  
Middle Group

To explore the effect of tissue metabolism of sodium alginate microspheres on liver cancer and the correlation between interventional treatment of liver cancer using alginate microspheres and prognosis of liver cancer in rabbits, in order to provide reliable data for human clinical study. Rabbit liver cancer model was established through direct inoculation of liver cancer tissues. Rabbits in experimental group were treated with hepatic arterial embolization (HAE) as follows: sodium alginate microspheres was injected through femoral artery to three sites which was 0.5 cm (proximal), 2 cm (middle), and 3.5 cm (distal) far from the lesion, respectively to block the tumor's nutrient supply. Short-term clinical efficacy, 3 month survival rate, 6-month mortality rate, 1-year survival rate, and adverse reactions were measured. The complete remission rates of proximal group, middle group, and distal group was 80%, 40%, and 20%, respectively. The complete remission rate of proximal group was significantly higher than that of middle group or distal group, with significantly higher complete remission rate of middle group compared with distal group (P < 0.05). In terms of progress, a significant difference was seen between proximal group and distal group (P < 0.01). 3-month and 1-year survival rates were increased along with the decrease of distance from injection position to the lesion with the correlation equation of y = –15.567x + 104.47 (R2 = 0.9429) and y = –13.333x + 91.133 (R2 = 0.9639). Six-month mortality rate was decreased along with the decrease of distance from injection position to the lesion with the correlation equation of y = 15.343x – 5.9967 (R2 = 0.9943). The prognosis was correlated with the injection position of alginate microspheres. The closer the injection position to the lesion, the better prognosis.

Survival of differentiated thyroid carcinoma studied in 500 patients.

1997 ◽  
Vol 15 (5) ◽  
pp. 2067-2075 ◽  
Author(s):  
H Lerch ◽  
O Schober ◽  
T Kuwert ◽  
H B Saur
Keyword(s):  
Survival Rate ◽  
Thyroid Carcinoma ◽  
Metastatic Disease ◽  
Locoregional Recurrence ◽  
Radioactive Iodine ◽  
Tumor Stage ◽  
Differentiated Thyroid Carcinoma ◽  
High Dose ◽  
External Radiotherapy ◽  
Kaplan Meier

PURPOSE To analyze the factors that influence survival of patients with differentiated thyroid carcinoma treated by surgical thyroidectomy, radioactive iodine, and early surgical reintervention with compartment-oriented lymphadenectomy in the case of locoregional recurrence. METHODS The survival of 500 patients with differentiated thyroid carcinoma was analyzed retrospectively with regard to mortality and survival rate (Kaplan-Meier). A total of 301 patients had papillary and 199 follicular thyroid carcinoma. The mean age of the 380 women and 120 men was 46.8 +/- 16.4 years at presentation. All patients were treated by surgical thyroidectomy, high-dose radioactive iodine, and early surgical reintervention with compartment-oriented lymphadenectomy in cases of locoregional recurrence, without routine adjuvant external radiotherapy of the neck. Patients were monitored up to 23 years, with a median follow-up time of 5.6 years. RESULTS Twenty-nine of 500 patients died, 19 of thyroid cancer. The corrected overall 5-year survival rate (Kaplan-Meier) was 0.92. Among patients with tumor stage pT1-3NO-1MO (low risk), none died of thyroid carcinoma (5-year survival rate, 0.97); in patients with tumor stage pT4 and/or M1 (high risk), the 5-year survival rate was 0.83. The cause of death was locoregional recurrence in eight and metastatic disease in 11. Using multivariate analysis, risk factors that significantly influence survival were local invasion (pT4), metastatic disease (M1), and age. CONCLUSION In differentiated thyroid carcinoma, the use of total surgical thyroidectomy followed by high-dose radioiodine therapy and early surgical reintervention in case of locoregional recurrence yields high survival rates, even without adjuvant external radiotherapy of the neck.

scholarly journals Anaplastic Transformation of Papillary Thyroid Cancer in the Retroperitoneum

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
James P. Solomon ◽  
Fang Wen ◽  
Lily J. Jih
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Rare Case ◽  
Case Reports ◽  
Anaplastic Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Cervical Lymph Nodes ◽  
Anaplastic Transformation ◽  
Metastatic Sites ◽  
Aggressive Variant

Anaplastic thyroid carcinoma is an aggressive variant of thyroid cancer that in most cases arises from anaplastic transformation of terminally differentiated thyroid carcinomas. This process usually occurs in the thyroid or cervical lymph nodes. Anaplastic transformation in distant metastatic sites is exceedingly rare, only previously documented in a few case reports. We report a rare case of anaplastic transformation of papillary thyroid carcinoma within a large retroperitoneal metastasis in a 64-year-old male 30 years after the initial diagnosis.

Sign in / Sign up

Export Citation Format

Share Document